Research field (7)：
Environmental and pharmaceutical development resources
, Nutrition and health science
, Pharmaceuticals - chemistry and drug development
, Immunology
, Other
, Allergies and connective tissue disease
, Hematology and oncology
Research theme for competitive and other funds (25)：
2022 - 2025 Development of radio-theranostics drugs against cancers using anti-EphA2 antibody
2021 - 2024 Establishment of a new preventive strategy based on the interaction of NK cells and prostate cancer stem cells
2019 - 2022 Practical research for biomarkers predicting tumorigenesis in polymyositis and dermatomyositis
2016 - 2019 Role of contraction-dependent myokines on the immune system
2014 - 2018 Preparation of microRNA from saliva and detection of cancer and prediction of drug sensitivity using saliva
2013 - 2016 Development of diagnostic system with high specificity and sensitivity for exosome derived from gynecologic cancer
2011 - 2014 Development of new target therapy for endometrial cancer stem cells
2010 - 2012 Research for novel diagnostic marker of gynecologic tumors and establishment of rapid and low invasive detection system by super-targeting antibody.
2005 - 2009 Selective targeted drug and gene delivery for cancer treatment
2007 - 2008 Development of new strategy for cord blood transplantation using enhancedleukemia-specific immune response with donor T cell
2007 - 2008 Research and development of low-invasive and high-sensitive detection system for novel tumor markers by super-targeting monoclonal antibody
2005 - 2006 Development of virus-specific immunocellular therapy after cord blood transplantation
2004 - 2005 Classification of mechanism of androgen independency in prostate cancer
2000 - 2004 腫瘍の特異的標的化を目指した遺伝子治療法の開発
2002 - 2003 Analysis of interaction of CD40 and CD40-ligand in autoimmune diseases and research for regulation drugs.
2001 - 2001 CD40リガンドを用いたヒト白血病に対する遺伝子治療の研究
2000 - 2001 Reseach for the mechanism of over-expression of soluble CD40-ligand and regulating drugs.
2000 - 2000 CD40リガンドを用いたヒト白血病に対する遺伝子治療の研究
1995 - 1997 Studies on the differention and activation mechanisms of T cell vi lymphocye functioning antigen (LFA).
Taiga Seki, Yui Shimizu, Kyota Ishii, Yuzuki Takahama, Kazunori Kato, Tomohiro Yano. Nk cells can preferentially target prostate cancer stem-like cells via the trail/dr5 signaling pathway. Biomolecules. 2021. 11. 11
Kouki Okita, Kazuki Imai, Kazunori Kato, Reiko Sugiura, Yuichi Endo, Kazue Masuko, Yoshihisa Tomioka, Takashi Masuko. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. Biochemical and Biophysical Research Communications. 2021. 576. 59-65
Eri Watanabe, Kazunori Kato, Takahisa Gono, Emiko Chiba, Chihiro Terai, Shigeru Kotake. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity. Rheumatology (Oxford, England). 2021. 60. 1. 322-332
